schliessen

Filtern

 

Bibliotheken

Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor

Nitric oxide synthase (NOS), an important bioregulator of a variety of biological processes, is overexpressed in colonic tumors of humans and rodents. In this study, effects of l-N G-nitroarginine methyl ester (L-NAME), a NOS inhibitor, on development of aberrant crypt foci (ACF) induced by azoxymet... Full description

Journal Title: Cancer letters 2000, Vol.148 (1), p.33-37
Main Author: Kawamori, Toshihiko
Other Authors: Takahashi, Mami , Watanabe, Kouji , Ohta, Toshihisa , Nakatsugi, Seiichi , Sugimura, Takashi , Wakabayashi, Keiji
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: Shannon: Elsevier Ireland Ltd
ID: ISSN: 0304-3835
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_crossref_primary_10_1016_S0304_3835_99_00310_9
title: Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor
format: Article
creator:
  • Kawamori, Toshihiko
  • Takahashi, Mami
  • Watanabe, Kouji
  • Ohta, Toshihisa
  • Nakatsugi, Seiichi
  • Sugimura, Takashi
  • Wakabayashi, Keiji
subjects:
  • Aberrant crypt foci
  • Animals
  • Anticarcinogenic Agents - administration & dosage
  • Anticarcinogenic Agents - pharmacology
  • Anticarcinogenic Agents - therapeutic use
  • Antigens, Nuclear
  • Antineoplastic agents
  • Azoxymethane
  • Biological and medical sciences
  • Body Weight - drug effects
  • Carcinogenesis, carcinogens and anticarcinogens
  • Carcinogens
  • Cell Division - drug effects
  • Cell Nucleus - chemistry
  • Cell Nucleus - drug effects
  • Cell Nucleus - pathology
  • Chemical agents
  • Chemoprevention
  • Colon
  • Colon - drug effects
  • Colon - pathology
  • Colonic Neoplasms - chemically induced
  • Colonic Neoplasms - enzymology
  • Colonic Neoplasms - pathology
  • Colonic Neoplasms - prevention & control
  • General aspects
  • Intestinal Mucosa - drug effects
  • Intestinal Mucosa - pathology
  • Male
  • Medical sciences
  • NG-Nitroarginine Methyl Ester - administration & dosage
  • NG-Nitroarginine Methyl Ester - adverse effects
  • NG-Nitroarginine Methyl Ester - pharmacology
  • NG-Nitroarginine Methyl Ester - therapeutic use
  • Nitric Oxide Synthase - antagonists & inhibitors
  • Nitric oxide synthase inhibitor
  • Nuclear Proteins - analysis
  • Pharmacology. Drug treatments
  • Precancerous Conditions - chemically induced
  • Precancerous Conditions - drug therapy
  • Precancerous Conditions - enzymology
  • Precancerous Conditions - pathology
  • Precancerous Conditions - prevention & control
  • Rats
  • Rats, Inbred F344
  • Tumors
ispartof: Cancer letters, 2000, Vol.148 (1), p.33-37
description: Nitric oxide synthase (NOS), an important bioregulator of a variety of biological processes, is overexpressed in colonic tumors of humans and rodents. In this study, effects of l-N G-nitroarginine methyl ester (L-NAME), a NOS inhibitor, on development of aberrant crypt foci (ACF) induced by azoxymethane (AOM) in F344 male rats were investigated. Six-week-old male F344 rats were fed diets containing 0 or 100 ppm L-NAME, and given s.c. injections of AOM at 15 mg/kg body wt. once a week for 2 weeks. At 17 weeks of age, all animals were sacrificed and their colons were evaluated for numbers of ACF. Feeding of 100 ppm L-NAME inhibited the development of ACF in different sizes by 24–39%, those containing four or more crypts being most markedly affected. Assessment of silver-stained nucleolar organizer regions protein (AgNORs)/nucleus further revealed a 44% reduction by administration of L-NAME. These results suggest that the NOS inhibitor, L-NAME, may be an effective chemopreventive agent against colon carcinogenesis due to depression of cell proliferation.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0304-3835
fulltext: fulltext
issn:
  • 0304-3835
  • 1872-7980
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK1.9862121
LOCALfalse
PrimoNMBib
record
control
sourceidpubmed_cross
recordidTN_cdi_crossref_primary_10_1016_S0304_3835_99_00310_9
sourceformatXML
sourcesystemPC
sourcerecordid10680590
originalsourceidFETCH-LOGICAL-c381t-84bfe18a79834d6685ce1253eba71951a546102d1cec0e01226cace3008afee43
addsrcrecordideNqFkU1v1DAQQC0EokvhJ4B84ACHtOM4TmxxQKjio1IlDi1ny5lMVKNdO7K9VcOvx-1WgLj05IPfG4-eGXst4ESA6E8vQULXSC3VO2PeA0gBjXnCNkIPbTMYDU_Z5g9yxF7k_BMAVDeo5-xIQK9BGdiw6XK_LIly9jHwOHP3K96uOyrXLlDjw7RHmjjGbQweuRspJRcKx7Quhc8RPR9X7njwJdX7eOsn4nkNVc_Efbj2oy8xvWTPZrfN9OrhPGY_vny-OvvWXHz_en726aJBqUVpdDfOJLSr28tu6nutkESrJI1uEEYJp7peQDsJJAQC0bY9OiQJoN1M1Mljpg5zMcWcE812SX7n0moF2Ltq9r6avUtijbH31ayp3puDt-zHHU3_WIdMFXj7ALiMbjvXCOjzX65VRg99xT789z764kpNW5Lz20e3-HiwqSa68ZRsRk-hfoBPhMVO0T8y4TejSJ13
sourcetypeAggregation Database
isCDItrue
recordtypearticle
display
typearticle
titleSuppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor
sourceAlma/SFX Local Collection
creatorKawamori, Toshihiko ; Takahashi, Mami ; Watanabe, Kouji ; Ohta, Toshihisa ; Nakatsugi, Seiichi ; Sugimura, Takashi ; Wakabayashi, Keiji
creatorcontribKawamori, Toshihiko ; Takahashi, Mami ; Watanabe, Kouji ; Ohta, Toshihisa ; Nakatsugi, Seiichi ; Sugimura, Takashi ; Wakabayashi, Keiji
descriptionNitric oxide synthase (NOS), an important bioregulator of a variety of biological processes, is overexpressed in colonic tumors of humans and rodents. In this study, effects of l-N G-nitroarginine methyl ester (L-NAME), a NOS inhibitor, on development of aberrant crypt foci (ACF) induced by azoxymethane (AOM) in F344 male rats were investigated. Six-week-old male F344 rats were fed diets containing 0 or 100 ppm L-NAME, and given s.c. injections of AOM at 15 mg/kg body wt. once a week for 2 weeks. At 17 weeks of age, all animals were sacrificed and their colons were evaluated for numbers of ACF. Feeding of 100 ppm L-NAME inhibited the development of ACF in different sizes by 24–39%, those containing four or more crypts being most markedly affected. Assessment of silver-stained nucleolar organizer regions protein (AgNORs)/nucleus further revealed a 44% reduction by administration of L-NAME. These results suggest that the NOS inhibitor, L-NAME, may be an effective chemopreventive agent against colon carcinogenesis due to depression of cell proliferation.
identifier
0ISSN: 0304-3835
1EISSN: 1872-7980
2DOI: 10.1016/S0304-3835(99)00310-9
3PMID: 10680590
4CODEN: CALEDQ
languageeng
publisherShannon: Elsevier Ireland Ltd
subjectAberrant crypt foci ; Animals ; Anticarcinogenic Agents - administration & dosage ; Anticarcinogenic Agents - pharmacology ; Anticarcinogenic Agents - therapeutic use ; Antigens, Nuclear ; Antineoplastic agents ; Azoxymethane ; Biological and medical sciences ; Body Weight - drug effects ; Carcinogenesis, carcinogens and anticarcinogens ; Carcinogens ; Cell Division - drug effects ; Cell Nucleus - chemistry ; Cell Nucleus - drug effects ; Cell Nucleus - pathology ; Chemical agents ; Chemoprevention ; Colon ; Colon - drug effects ; Colon - pathology ; Colonic Neoplasms - chemically induced ; Colonic Neoplasms - enzymology ; Colonic Neoplasms - pathology ; Colonic Neoplasms - prevention & control ; General aspects ; Intestinal Mucosa - drug effects ; Intestinal Mucosa - pathology ; Male ; Medical sciences ; NG-Nitroarginine Methyl Ester - administration & dosage ; NG-Nitroarginine Methyl Ester - adverse effects ; NG-Nitroarginine Methyl Ester - pharmacology ; NG-Nitroarginine Methyl Ester - therapeutic use ; Nitric Oxide Synthase - antagonists & inhibitors ; Nitric oxide synthase inhibitor ; Nuclear Proteins - analysis ; Pharmacology. Drug treatments ; Precancerous Conditions - chemically induced ; Precancerous Conditions - drug therapy ; Precancerous Conditions - enzymology ; Precancerous Conditions - pathology ; Precancerous Conditions - prevention & control ; Rats ; Rats, Inbred F344 ; Tumors
ispartofCancer letters, 2000, Vol.148 (1), p.33-37
rights
02000 Elsevier Science Ireland Ltd
12000 INIST-CNRS
lds50peer_reviewed
citedbyFETCH-LOGICAL-c381t-84bfe18a79834d6685ce1253eba71951a546102d1cec0e01226cace3008afee43
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1259876$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10680590$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Kawamori, Toshihiko
1Takahashi, Mami
2Watanabe, Kouji
3Ohta, Toshihisa
4Nakatsugi, Seiichi
5Sugimura, Takashi
6Wakabayashi, Keiji
title
0Suppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor
1Cancer letters
addtitleCancer Lett
descriptionNitric oxide synthase (NOS), an important bioregulator of a variety of biological processes, is overexpressed in colonic tumors of humans and rodents. In this study, effects of l-N G-nitroarginine methyl ester (L-NAME), a NOS inhibitor, on development of aberrant crypt foci (ACF) induced by azoxymethane (AOM) in F344 male rats were investigated. Six-week-old male F344 rats were fed diets containing 0 or 100 ppm L-NAME, and given s.c. injections of AOM at 15 mg/kg body wt. once a week for 2 weeks. At 17 weeks of age, all animals were sacrificed and their colons were evaluated for numbers of ACF. Feeding of 100 ppm L-NAME inhibited the development of ACF in different sizes by 24–39%, those containing four or more crypts being most markedly affected. Assessment of silver-stained nucleolar organizer regions protein (AgNORs)/nucleus further revealed a 44% reduction by administration of L-NAME. These results suggest that the NOS inhibitor, L-NAME, may be an effective chemopreventive agent against colon carcinogenesis due to depression of cell proliferation.
subject
0Aberrant crypt foci
1Animals
2Anticarcinogenic Agents - administration & dosage
3Anticarcinogenic Agents - pharmacology
4Anticarcinogenic Agents - therapeutic use
5Antigens, Nuclear
6Antineoplastic agents
7Azoxymethane
8Biological and medical sciences
9Body Weight - drug effects
10Carcinogenesis, carcinogens and anticarcinogens
11Carcinogens
12Cell Division - drug effects
13Cell Nucleus - chemistry
14Cell Nucleus - drug effects
15Cell Nucleus - pathology
16Chemical agents
17Chemoprevention
18Colon
19Colon - drug effects
20Colon - pathology
21Colonic Neoplasms - chemically induced
22Colonic Neoplasms - enzymology
23Colonic Neoplasms - pathology
24Colonic Neoplasms - prevention & control
25General aspects
26Intestinal Mucosa - drug effects
27Intestinal Mucosa - pathology
28Male
29Medical sciences
30NG-Nitroarginine Methyl Ester - administration & dosage
31NG-Nitroarginine Methyl Ester - adverse effects
32NG-Nitroarginine Methyl Ester - pharmacology
33NG-Nitroarginine Methyl Ester - therapeutic use
34Nitric Oxide Synthase - antagonists & inhibitors
35Nitric oxide synthase inhibitor
36Nuclear Proteins - analysis
37Pharmacology. Drug treatments
38Precancerous Conditions - chemically induced
39Precancerous Conditions - drug therapy
40Precancerous Conditions - enzymology
41Precancerous Conditions - pathology
42Precancerous Conditions - prevention & control
43Rats
44Rats, Inbred F344
45Tumors
issn
00304-3835
11872-7980
fulltexttrue
rsrctypearticle
creationdate2000
recordtypearticle
recordideNqFkU1v1DAQQC0EokvhJ4B84ACHtOM4TmxxQKjio1IlDi1ny5lMVKNdO7K9VcOvx-1WgLj05IPfG4-eGXst4ESA6E8vQULXSC3VO2PeA0gBjXnCNkIPbTMYDU_Z5g9yxF7k_BMAVDeo5-xIQK9BGdiw6XK_LIly9jHwOHP3K96uOyrXLlDjw7RHmjjGbQweuRspJRcKx7Quhc8RPR9X7njwJdX7eOsn4nkNVc_Efbj2oy8xvWTPZrfN9OrhPGY_vny-OvvWXHz_en726aJBqUVpdDfOJLSr28tu6nutkESrJI1uEEYJp7peQDsJJAQC0bY9OiQJoN1M1Mljpg5zMcWcE812SX7n0moF2Ltq9r6avUtijbH31ayp3puDt-zHHU3_WIdMFXj7ALiMbjvXCOjzX65VRg99xT789z764kpNW5Lz20e3-HiwqSa68ZRsRk-hfoBPhMVO0T8y4TejSJ13
startdate2000
enddate2000
creator
0Kawamori, Toshihiko
1Takahashi, Mami
2Watanabe, Kouji
3Ohta, Toshihisa
4Nakatsugi, Seiichi
5Sugimura, Takashi
6Wakabayashi, Keiji
general
0Elsevier Ireland Ltd
1Elsevier
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
sort
creationdate2000
titleSuppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor
authorKawamori, Toshihiko ; Takahashi, Mami ; Watanabe, Kouji ; Ohta, Toshihisa ; Nakatsugi, Seiichi ; Sugimura, Takashi ; Wakabayashi, Keiji
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c381t-84bfe18a79834d6685ce1253eba71951a546102d1cec0e01226cace3008afee43
rsrctypearticles
prefilterarticles
languageeng
creationdate2000
topic
0Aberrant crypt foci
1Animals
2Anticarcinogenic Agents - administration & dosage
3Anticarcinogenic Agents - pharmacology
4Anticarcinogenic Agents - therapeutic use
5Antigens, Nuclear
6Antineoplastic agents
7Azoxymethane
8Biological and medical sciences
9Body Weight - drug effects
10Carcinogenesis, carcinogens and anticarcinogens
11Carcinogens
12Cell Division - drug effects
13Cell Nucleus - chemistry
14Cell Nucleus - drug effects
15Cell Nucleus - pathology
16Chemical agents
17Chemoprevention
18Colon
19Colon - drug effects
20Colon - pathology
21Colonic Neoplasms - chemically induced
22Colonic Neoplasms - enzymology
23Colonic Neoplasms - pathology
24Colonic Neoplasms - prevention & control
25General aspects
26Intestinal Mucosa - drug effects
27Intestinal Mucosa - pathology
28Male
29Medical sciences
30NG-Nitroarginine Methyl Ester - administration & dosage
31NG-Nitroarginine Methyl Ester - adverse effects
32NG-Nitroarginine Methyl Ester - pharmacology
33NG-Nitroarginine Methyl Ester - therapeutic use
34Nitric Oxide Synthase - antagonists & inhibitors
35Nitric oxide synthase inhibitor
36Nuclear Proteins - analysis
37Pharmacology. Drug treatments
38Precancerous Conditions - chemically induced
39Precancerous Conditions - drug therapy
40Precancerous Conditions - enzymology
41Precancerous Conditions - pathology
42Precancerous Conditions - prevention & control
43Rats
44Rats, Inbred F344
45Tumors
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Kawamori, Toshihiko
1Takahashi, Mami
2Watanabe, Kouji
3Ohta, Toshihisa
4Nakatsugi, Seiichi
5Sugimura, Takashi
6Wakabayashi, Keiji
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
jtitleCancer letters
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Kawamori, Toshihiko
1Takahashi, Mami
2Watanabe, Kouji
3Ohta, Toshihisa
4Nakatsugi, Seiichi
5Sugimura, Takashi
6Wakabayashi, Keiji
formatjournal
genrearticle
ristypeJOUR
atitleSuppression of azoxymethane-induced colonic aberrant crypt foci by a nitric oxide synthase inhibitor
jtitleCancer letters
addtitleCancer Lett
date2000
risdate2000
volume148
issue1
spage33
epage37
pages33-37
issn0304-3835
eissn1872-7980
codenCALEDQ
abstractNitric oxide synthase (NOS), an important bioregulator of a variety of biological processes, is overexpressed in colonic tumors of humans and rodents. In this study, effects of l-N G-nitroarginine methyl ester (L-NAME), a NOS inhibitor, on development of aberrant crypt foci (ACF) induced by azoxymethane (AOM) in F344 male rats were investigated. Six-week-old male F344 rats were fed diets containing 0 or 100 ppm L-NAME, and given s.c. injections of AOM at 15 mg/kg body wt. once a week for 2 weeks. At 17 weeks of age, all animals were sacrificed and their colons were evaluated for numbers of ACF. Feeding of 100 ppm L-NAME inhibited the development of ACF in different sizes by 24–39%, those containing four or more crypts being most markedly affected. Assessment of silver-stained nucleolar organizer regions protein (AgNORs)/nucleus further revealed a 44% reduction by administration of L-NAME. These results suggest that the NOS inhibitor, L-NAME, may be an effective chemopreventive agent against colon carcinogenesis due to depression of cell proliferation.
copShannon
pubElsevier Ireland Ltd
pmid10680590
doi10.1016/S0304-3835(99)00310-9